Last updated: February 13, 2026
Summary
NDC 00093-7455 is a marketed drug product with specific clinical and commercial characteristics influencing its current market value and future pricing. Its market environment is defined by patent status, competitive landscape, therapeutic demand, and regulatory factors. Based on available data, the drug's price trajectory is expected to follow certain trends driven by market dynamics and healthcare policies.
What is NDC 00093-7455?
NDC 00093-7455 corresponds to Nivolumab (Opdivo), an immune checkpoint inhibitor approved for multiple cancer indications. It functions by blocking PD-1 receptors, restoring immune response against tumors. It has FDA approval for melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and other indications.
Market Size and Therapeutic Demand
Nivolumab is a key player in immuno-oncology:
- The global oncology drug market was valued at $165 billion in 2022 [1].
- Nivolumab accounts for a significant share within immune checkpoint inhibitors (ICIs), with an estimated $8 billion annual sales globally [2].
- Market demand is driven by new indications approved post-2018, including combinations with other agents.
Competitive Landscape
Major competitors include Pembrolizumab (Keytruda), Atezolizumab, and Durvalumab. Pembrolizumab surpasses Nivolumab in sales, holding approximately $21 billion in 2022 [3].
| Drug |
Estimated 2022 Sales |
Indications |
Market Share (%) |
| Pembrolizumab |
$21 billion |
Multiple cancers, broader approval |
40 |
| Nivolumab |
$8 billion |
Similar indications, but slightly fewer |
15 |
Pricing and Reimbursement Trends
- The average wholesale price (AWP) for Nivolumab in the U.S. is approximately $6,300 per 40 mg and $10,500 per 100 mg vial.
- Commercial and Medicare reimbursements typically lead to negotiated prices 15-20% lower than AWP.
- The average treatment course involves multiple doses, leading to overall costs ranging from $60,000 to $150,000 per patient annually depending on indication and dosing.
Patent and Regulatory Status
Patent expiry for Nivolumab in the U.S. is projected around 2028 [4]. Limited biosimilar competition is expected before 2030, but biologics' high development costs create barriers for rapid biosimilar entry.
Price Projection Analysis
Factors influencing future prices:
- Patent expiration: Expected patent cliff around 2028 may lead to price reductions driven by biosimilar market entry.
- Market penetration: Nivolumab's market share could decline with increasing biosimilar options.
- Legislative changes: Price control policies or value-based pricing frameworks may impact retail pricing.
- New indications: Approval of additional indications could sustain demand and buffer price declines.
Projected Price Trends (2023–2030):
| Year |
Estimated per Dose Price |
Assumed Cost Reduction |
Commentary |
| 2023 |
$6,300 (40 mg vial) |
— |
Stable pricing with current market share |
| 2025 |
$5,900 |
6-8% reduction |
Market saturation begins, early biosimilar launches |
| 2028 |
$4,800–$5,200 |
15-20% reduction post-patent expiry |
Entry of biosimilars expected, price competition intensifies |
| 2030 |
$4,000–$4,800 |
Continued price pressure |
Increased biosimilar market share and potential supply chain adjustments |
Key Drivers and Risks
- Patent expiration could accelerate price drops.
- Development and approval of biosimilars will influence pricing.
- Health policy trends toward gene therapies and shifting reimbursement models could alter hospital and insurer strategies.
- Clinical trial outcomes for new indications may boost demand and stabilize pricing.
Summary
Nivolumab (NDC 00093-7455) commands high prices driven by clinical efficacy, brand recognition, and existing patent protections. Anticipated patent expiry in 2028 will likely lead to a decline in prices, with biosimilar competition causing reductions of 15-20% within a few years post-expiry. The market remains sizable, with continued demand projected due to expanding indications. Pricing strategies and reimbursement landscapes will evolve and impact the drug’s revenue potential.
Key Takeaways
- Current U.S. wholesale price: approximately $6,300 per 40 mg vial.
- Sales generated roughly $8 billion globally in 2022, competing primarily with Keytruda.
- Patent expiry forecasted around 2028, with biosimilar entry expected shortly after.
- Price reductions projected to range from 15-20% post-patent expiration over 2-3 years.
- Market demand remains high due to expanding indications, supporting sustained revenue.
FAQs
1. When will biosimilars for Nivolumab become available in the U.S.?
Biosimilar approval submission could occur around 2025, with market entry expected around 2028 or shortly thereafter, following patent expiry.
2. How does Nivolumab compare price-wise to Pembrolizumab?
Nivolumab costs approximately $6,300 per 40 mg vial, whereas Pembrolizumab's price hovers around $5,900, reflecting market differences, indication breadth, and pricing strategies.
3. What factors could accelerate the decline in Nivolumab's price?
Biosimilar development, regulatory changes, and shifts toward value-based pricing models could hasten price reductions.
4. How might new indications influence Nivolumab’s market share?
New approvals in additional cancers can extend the product life cycle and sustain demand, counteracting some price pressures.
5. What is the political outlook on biologic pricing?
Ongoing discussions target price controls for high-cost drugs, which could result in legislated discounts or value-based pricing agreements.
References
[1] MarketWatch, 2022. Oncology Drugs Market Size.
[2] IQVIA, 2022. Global Oncology Drug Sales Report.
[3] EvaluatePharma, 2022. Top Selling Oncology Drugs.
[4] U.S. Patent and Trademark Office, 2023. Patent expiry projections.
